Endpoint
Serum free thyroxine (FT4)
CAT:outcome/serum-free-thyroxinereported in pmol/L1 finding from 1 compound
What moved it
How to read these marks1 finding · 1 compound · 1 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| selenium atom | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
Every finding here is a null result.
Measured, no effect detected
1 finding
selenium atom — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis found no statistically significant difference in FT3 and FT4 level after 3 or 6 months of Se treatment (Fig. S1, Supplemental Digital Content, https://links.lww.com/MD/P797).”
Quoted verbatim from Clinical efficacy of selenium supplementation in patients with Hashimoto thyroiditis: A systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- typically 200 μg/d
- Population
- Adults with Hashimoto thyroiditis, with or without levothyroxine; selenium against placebo, no treatment or levothyroxine alone; 3- and 6-month timepoints
Clinical efficacy of selenium supplementation in patients with Hashimoto thyroiditis: A systematic review and meta-analysis.2025PMID:40898469Permalink
How it is measured
Free (unbound) thyroxine concentration in serum or plasma by clinical immunoassay, in pmol/L (or ng/dL as reported). The assay platform and unit are recorded with each finding.
Sources cited
1 paper
- Subject
- serum free thyroxine (ft4)
- Findings
- 1
- Papers
- 1